Abstract

Hydrogen sulfide (H 2 S) has recently emerged as a novel gaseous mediator with protective actions in the treatment of pulmonary arterial hypertension (PAH). However, the therapeutic potential of H 2 S in PAH has been substantially hampered due to the lack of appropriate donors that could mimic the slow and continuous generation of H 2 S in vivo . Large porous microspheres (LPMs) have low density and large surface area leading to excellent absorption capabilities and aerodynamic properties. They are extensively studied as pulmonary delivery carriers for controlled and sustained release of drug molecules in the treatment of pulmonary disorders. Therefore, we hypothesized that LPMs containing H 2 S-releasing aspirin derivative (ACS14), a novel synthetic H 2 S donor may be a feasible option to facilitate the use of H 2 S in PAH treatment. LPMs were prepared with a biodegradable polymer , poly(lactic- co -glycolic acid) (PLGA) by a microfluidic technique. Surface morphology , lung deposition characteristics, safety and H 2 S release profiles of the formulation were evaluated. The resulting ACS14-containing LPMs (ACS14 MSs) displayed excellent aerodynamic properties (mass median aerodynamic diameter of 4.4 ± 0.4 μm), desirable drug loading and entrapment efficiency (25.8 ± 2.7% and 77.4 ± 6.9%, respectively) with slow and sustained H 2 S release for 24 h and negligible cytotoxicity (~95% cell viability). Daily intratracheally administered with ACS14 MSs elicited improvement in the severity of PAH in a rat model of monocrotaline-induced PAH, with comparable efficacy to oral administration with sildenafil , a conventional PAH treatment. It also inhibited the process of endothelial-to-mesenchymal transition (EndMT), an important process in vascular remodeling of PAH by suppressing the induction of NF-κB-Snail pathway. Moreover, ACS14 MSs dose-dependently inhibited TGF-β1-induced EndMT and the activation of NF-κB-Snail pathway in human pulmonary artery endot